COVID-19-Induced Diabetes: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Barbara Grubišić
,
Luka Švitek
,
Klara Ormanac
,
Dea Sabo
,
Ivica Mihaljević
,
Ines Bilić-Ćurčić
,
Tea Omanović Kolarić

The COVID-19 pandemic has revealed a significant association between SARS-CoV-2 infection and diabetes, whereby individuals with diabetes are more susceptible to severe disease and higher mortality rates. The association between diabetes and COVID-19 is probably bidirectional, recent findings suggest a reciprocal relationship between COVID-19 and diabetes, wherein COVID-19 may contribute to developing new-onset diabetes and worsen existing metabolic abnormalities.

  • COVID-19
  • SARS-CoV-2
  • diabetes

1. Introduction

During the COVID-19 pandemic, it has been observed that individuals with diabetes have a significantly increased risk of developing a severe form of the illness and a higher mortality rate following infection with SARS-CoV-2 [1]. This is consistent with the long-established connection between diabetes and increased susceptibility and severity of infections, which is attributed to hyperglycaemia. Hyperglycaemia leads to cytokine dysregulation and immune response alteration, resulting in a pro-inflammatory and procoagulant state that promotes immune dysfunction through various pathways [2][3]. Individuals with diabetes also exhibit increased rates of hospitalization and mortality resulting from infections. The risk of infections escalates with worsening glycaemic control, with type 1 diabetes patients being at greater risk [4][5][6]. Individuals diagnosed with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) frequently present with comorbid medical conditions, such as hypertension, obesity, and cardiovascular disease, which have been linked to an increased risk of contracting COVID-19 as well as an increased risk of infection-related mortality [7]. As the COVID-19 pandemic is constantly evolving, it has become more apparent that individuals with COVID-19 may experience hyperglycaemia, regardless of whether they have diabetes. This observation could imply a mutually influential relationship between COVID-19 and diabetes. Recent research suggests that a combination of insulin resistance and possible issues with insulin secretion may be responsible for the development of hyperglycaemia in COVID-19 patients who did not previously have diabetes [8][9].
The SARS-CoV-2 virus has the ability to attach itself to receptors called angiotensin-converting enzyme 2 (ACE2), which are present in various crucial metabolic organs and tissues, such as pancreatic 𝛽-cells, adipose tissue, kidneys, and the small intestine. This suggests that SARS-CoV-2 may potentially interfere with the glucometabolic pathways, leading to complications and even contributing to the development of new disease mechanisms [1]. Various mechanisms have been suggested to explain the occurrence of diabetes in conjunction with COVID-19 infection, including direct invasion of 𝛽-cells by the virus, leading to their impaired function, induction of insulin resistance through systemic inflammation, or endocrine alterations inciting this response [10]. It is presently uncertain if the emergence of SARS-CoV-2-induced diabetes is due to established mechanisms of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2D) or if it constitutes an atypical diabetes form. It is unknown whether COVID-19 patients are still vulnerable to developing new-onset diabetes or diabetes-related complications even after virus clearance and recovery [2][3]. Furthermore, glucocorticoids, which are frequently prescribed for moderate to severe COVID-19 cases, have been known to cause hyperglycaemia and insulin resistance, which could contribute to the incidence of new-onset diabetes [11]. Some studies have found that COVID-19 patients who develop new-onset diabetes tend to have worse outcomes than those with no diabetes or with previous diabetes [11][12][13][14].

2. COVID-19-Induced Diabetes

The association between diabetes and COVID-19 is probably bidirectional. Diabetes is known as a serious disease and comorbidity associated with a more severe clinical presentation and worse prognosis in many infectious and other diseases [15][16][17][18][19][20][21][21]. New-onset hyperglycaemia has been increasingly observed in adults with no history of diabetes in association with COVID-19, accompanied with significant morbidity and mortality. Although infection-induced inflammation and cytokine activation leading to insulin resistance may cause stress hyperglycaemia, it is unknown to what extent the direct destruction of islet cells by the virus, resulting in decreased insulin production and release, contributes [9]. Interestingly, COVID-19 infection has been linked to the development of diabetes, evident through sudden onset hyperglycaemia in non-diabetic individuals, diabetic ketoacidosis in pre-existing diabetic patients with COVID-19, and the emergence of diabetes in patients with COVID-19 [13][22][23][24], shown in Table 1.
Table 1. Studies that have described new-onset diabetes in COVID-19 patients.
Authors Type of Study Country Number of Cases Results
Sathish et al. [25] Meta-analysis China, Italy, US 3711 patients 14.4% of the population had new-onset diabetes
Sathish et al. [26] Retrospective study India 102 patients 20.6% of the population had new-onset diabetes
Li et al. [11] Retrospective study China 453 patients 20.8% of the population had new-onset diabetes
Unsworth et al. [27] Retrospective study UK 30 children 80% increase in new-onset T1DM
Tittel et al. [28] Prospective study Germany Children from 216 paediatric diabetes centres T1DM incidence increased from 16.4 per 100,000 to 22.2 per 100,000
Salmi et al. [29] Retrospective study Finland Children admitted to PICU due to new-onset diabetes compared with the pre-pandemic period The number of children admitted to PICU due to new-onset diabetes increased from 6.25 in 2016 to 20 in 2020.
Montefusco et al. [23] Retrospective study Italy 551 patients 46% were hyperglycaemic
Kamrath et al. [30] Prospective study Germany 532 newly diagnosed T1DM The frequency of diabetic ketoacidosis was 44.7%
Fadini et al. [13] Retrospective study Italy 413 patients 5% had new-onset diabetes
Ghosh et al. [24] Retrospective study India 555 patients with new-onset diabetes Patients with new-onset diabetes had worse glycaemic parameters
Shrestha et al. [31] Meta-analysis US, China, France, India, Italy 1943 patients across seven studies The mortality rate in COVID-19-associated diabetes patients was 25%
Like other viruses, SARS-CoV-2 infections can trigger a stress response that may decrease insulin secretion, activate the release of cortisol and adrenaline, and stimulate excessive gluconeogenesis, leading to temporary hyperglycaemia. These mechanisms do not inevitably result in diabetes [32]. COVID-19 infection has been associated with a distinctive range of newly developed diabetes variations, including some that appear to be unique to the disease. While most large-scale studies have categorized new-onset diabetes as either type 1 or type 2, recent case reports have suggested that COVID-induced diabetes can take on different forms. Omotosho et al. presented a case study of a woman who developed latent autoimmune diabetes of adulthood (LADA) following a COVID-19 infection [33]. Positive tests for islet cell and glutamic acid decarboxylase (GAD) antibodies confirmed the patient’s type 1 diabetes diagnosis. Marchand et al. also reported a case of LADA in a patient infected with COVID-19 [34].
A random effects meta-analysis determined that the overall incidence of new-onset diabetes among COVID-19 patients was 14.4% [25]. Additionally, a systematic review and meta-analysis of eight cohort studies, which included over forty-seven million individuals, demonstrated that COVID-19 was associated with a 66% increase in the risk of diabetes compared to those who did not contract COVID-19. The risk was not influenced by variables such as age, gender, or study quality [35]. Patients with newly diagnosed diabetes as a result of COVID-19 have a greater risk of hospitalization and death compared to those who are normoglycaemic or have only temporary hyperglycaemia. These patients with pre-existing or new-onset diabetes associated with COVID-19 also have more severe complications, such as acute respiratory distress syndrome, acute renal failure, shock, and low albumin levels, compared to those with normal or temporarily elevated blood sugar levels [11]. Furthermore, patients with COVID-19 are also more prone to ketoacidosis [36][37][38], which could indicate the diabetogenic potential of SARS-CoV-2. The mechanisms mentioned were proposed by Sathish et al. [39] and some other authors [40][41]. Some studies showed that diabetes is related to prolonged hospitalization of patients with COVID-19 [42] and with worse disease outcomes [31][43][44][45][46][47][48][49][50]. It is also concluded that patients with diabetes mellitus are more prone to developing severe symptoms of COVID-19 [44][47][48][50]. Moreover, newly diagnosed diabetes during SARS-CoV-2 infection has been linked to an even worse prognosis than pre-existing, probably due to insufficient diabetes regulation [25][46][47][51].
A previous study that involved more than 180,000 veterans showed that individuals who had recovered from COVID-19 were 40% more likely to develop diabetes than those who had not previously been diagnosed with COVID-19. As mentioned, another study revealed that as much as 14% of individuals who were hospitalized for COVID-19 were subsequently diagnosed with diabetes [35]. Another meta-analysis that included 4,270,747 SARS-CoV-2 positive patients surviving the disease and 43,203,759 control patients demonstrated a higher risk of diagnosing diabetes in recovered COVID-19 patients than in the control group [35]. Those data could be in favour of the diabetogenic potential of SARS-CoV-2 or could have a connection with corticosteroid treatment, which can worsen hyperglycaemia, resulting in a negative impact on patients’ physiological processes [44][52]. However, the SARS-CoV-2 pandemic influenced diabetic patients in other ways, such as health availability and support, which were mostly insufficient, at least at the beginning of the pandemic [53][54][55][56].

2.1. Type 1 Diabetes Mellitus (T1DM)

Although type 1 diabetes is autoimmune in nature, its onset usually necessitates an environmental trigger, such as an infection [57]. In the case of SARS-CoV-2, it is suggested that direct infection, coupled with the inflammatory response and interactions with the renin–angiotensin system, can lead to damage to pancreatic cells and the development of new-onset diabetes. Case reports of individuals with recent SARS-CoV-2 infection presenting with new-onset T1DM and DKA suggest that SARS-CoV-2 infection may expedite the development of T1DM or elevate the susceptibility to its metabolic complications [28][29][30][58]. There is much speculation surrounding the suggestion that exposure to SARS-CoV-2 could have triggered the onset of T1DM, which may have contributed to the rise in DKA. However, there is insufficient evidence to confirm whether this new-onset diabetes represents classic T1DM or a distinct form of diabetes. It remains unclear whether the severe COVID-19-induced hyperglycaemia observed in some individuals would resolve over time, as was observed with SARS-CoV-1-induced diabetes [1]. The precise mechanisms by which SARS-CoV-2 increases the risk of T1DM are still being investigated. However, it is known that the destruction of 𝛽-cells can initiate the spread of epitopes, leading to the activation of CD-8 T cells and the production of a broader spectrum of autoantibodies that target various islet cells, such as insulin, glutamic acid decarboxylase, and protein tyrosine phosphatase. This autoimmune response depletes functional 𝛽-cells, resulting in hyperglycemia and the clinical manifestation of type 1 diabetes [59].

2.2. Type 2 Diabetes Mellitus (T2DM)

Studies have indicated that acute COVID-19 more often may exacerbate pre-existing prediabetes or T2DM [60]. Individuals who are hospitalized for acute COVID-19 infections may have undetected diabetes mellitus. The pandemic-related changes in lifestyle, such as decreased physical activity due to measures like lockdowns, may have played a role in the increased weight gain and glyco-metabolic syndrome observed in people with prediabetes. Such changes may also raise the risk of developing new-onset diabetes in the post-infectious stage [31]. COVID-19 can elevate stress hormones, such as adrenaline and cortisol, which may trigger the production of glucose, resulting in hyperglycaemia [61]. Also, direct cytotoxic injury to pancreatic cells caused by SARS-CoV-2 infection may result in reduced insulin production [62]. COVID-19 may exacerbate pre-existing T2DM or prediabetes. Certain studies suggest that these conditions are transient and may resolve with time, but this hypothesis requires ongoing investigation in the future [60].

2.3. COVID-19-Vaccine-Induced Diabetes Mellitus

There are speculations about the impact of COVID-19 vaccines on diabetes mellitus development. For now, there are mostly case reports for such events; patients are usually presenting with ketoacidosis [63][64][65], hyperglycaemia [66][67][68], or hyperosmolar state [67]. There were some observations that vaccines could precipitate hyperglycaemia and other complications in patients that already have diabetes [69], but a study conducted on 350,936 cases did not find such a link [70], as well as a study completed in paediatric patients [71]. Furthermore, there are reports about more frequent adverse reactions to the vaccines with diabetic patients [72][73], but other researchers did not find such a relation [74]. There were concerns that, since diabetes mellitus is a procoagulatory state, vaccines could precipitate thromboembolic incidents, but a study investigating coagulation pathways in T1DM and T2DM patients after vaccination did not find significant differences compared to healthy individuals [75]. Vaccines not only reduce the chance of severe clinical presentation and hospital admission in diabetic patients [76] but could also have a protective effect and reduce the possibility of developing diabetes mellitus after COVID-19 in healthy individuals [62][77]. Nevertheless, patients with diabetes mellitus have decreased antibody and memory 𝛽-cell response to the vaccine [74][78][79], and there are reports that vaccines could be less effective in those individuals [80][81].

This entry is adapted from the peer-reviewed paper 10.3390/ijms241411576

References

  1. Rubino, F.; Amiel, S.A.; Zimmet, P.; Alberti, G.; Bornstein, S.; Eckel, R.H.; Mingrone, G.; Boehm, B.; Cooper, M.E.; Chai, Z.; et al. New-Onset Diabetes in COVID-19. N. Engl. J. Med. 2020, 383, 789–790.
  2. Joshi, N.; Caputo, G.M.; Weitekamp, M.R.; Karchmer, A.W. Infections in patients with diabetes mellitus. N. Engl. J. Med. 1999, 341, 1906–1912.
  3. Al-Aly, Z.; Xie, Y.; Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021, 594, 259–264.
  4. Erener, S. Diabetes, infection risk and COVID-19. Mol. Metab. 2020, 39, 101044.
  5. Carey, I.M.; Critchley, J.A.; DeWilde, S.; Harris, T.; Hosking, F.J.; Cook, D.G. Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study. Diabetes Care 2018, 41, 513–521.
  6. Casqueiro, J.; Casqueiro, J.; Alves, C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J. Endocrinol. Metab. 2012, 16 Suppl 1, S27–S36.
  7. Zhu, L.; She, Z.G.; Cheng, X.; Qin, J.J.; Zhang, X.J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W.; et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020, 31, 1068–1077.e3.
  8. Apicella, M.; Campopiano, M.C.; Mantuano, M.; Mazoni, L.; Coppelli, A.; Del Prato, S. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020, 8, 782–792.
  9. Ceriello, A.; De Nigris, V.; Prattichizzo, F. Why is hyperglycaemia worsening COVID-19 and its prognosis? Diabetes Obes. Metab. 2020, 22, 1951–1952.
  10. Lazarus, G.; Audrey, J.; Wangsaputra, V.K.; Tamara, A.; Tahapary, D.L. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis. Diabetes Res. Clin. Pract. 2021, 171, 108561.
  11. Li, H.; Tian, S.; Chen, T.; Cui, Z.; Shi, N.; Zhong, X.; Qiu, K.; Zhang, J.; Zeng, T.; Chen, L.; et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes. Metab. 2020, 22, 1897–1906.
  12. Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: A multi-centre retrospective study. Diabetologia 2020, 63, 2102–2111.
  13. Fadini, G.P.; Morieri, M.L.; Boscari, F.; Fioretto, P.; Maran, A.; Busetto, L.; Bonora, B.M.; Selmin, E.; Arcidiacono, G.; Pinelli, S.; et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res. Clin. Pract. 2020, 168, 108374.
  14. Coppelli, A.; Giannarelli, R.; Aragona, M.; Penno, G.; Falcone, M.; Tiseo, G.; Ghiadoni, L.; Barbieri, G.; Monzani, F.; Virdis, A.; et al. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care 2020, 43, 2345–2348.
  15. Cheong, C.W.; Chen, C.L.; Li, C.H.; Seak, C.J.; Tseng, H.J.; Hsu, K.H.; Ng, C.J.; Chien, C.Y. Two-stage prediction model for in-hospital mortality of patients with influenza infection. BMC Infect. Dis. 2021, 21, 451.
  16. Andrade, F.B.; Gualberto, A.; Rezende, C.; Percegoni, N.; Gameiro, J.; Hottz, E.D. The Weight of Obesity in Immunity from Influenza to COVID-19. Front. Cell. Infect. Microbiol. 2021, 11, 638852.
  17. Shill, M.C.; Mohsin, M.N.A.B.; Showdagor, U.; Hasan, S.N.; Zahid, M.Z.I.; Khan, S.I.; Hossain, M.; Rahman, G.M.S.; Reza, H.M. Microbial sensitivity of the common pathogens for UTIs are declining in diabetic patients compared to non-diabetic patients in Bangladesh: An institution-based retrospective study. Heliyon 2023, 9, e12897.
  18. Wong, J.W.H.; Xu, R.H.; Ramm, O.; Tucker, L.Y.; Zaritsky, E.F. Urinary Tract Infections Among Gender Diverse People Assigned Female at Birth on Testosterone. Urogynecology 2023, 29, 295–301.
  19. Morbach, S.; Eckhard, M.; Lobmann, R.; Müller, E.; Reike, H.; Risse, A.; Rümenapf, G.; Spraul, M. Diabetic Foot Syndrome. Exp. Clin. Endocrinol. Diabetes 2023, 131, 84–93.
  20. Wu, H.; Lau, E.S.; Yang, A.; Zhang, X.; Fan, B.; Ma, R.C.; Kong, A.P.; Chow, E.; So, W.Y.; Chan, J.C.; et al. Age-specific population attributable risk factors for all-cause and cause-specific mortality in Type 2 diabetes: An analysis of a 6-year prospective cohort study of over 360,000 people in Hong Kong. PLoS Med. 2023, 20, e1004173.
  21. Beumer, M.C.; Koch, R.M.; van Beuningen, D.; OudeLashof, A.M.; van de Veerdonk, F.L.; Kolwijck, E.; van der Hoeven, J.G.; Bergmans, D.C.; Hoedemaekers, C.W.E. Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J. Crit. Care 2019, 50, 59–65.
  22. Metwally, A.A.; Mehta, P.; Johnson, B.S.; Nagarjuna, A.; Snyder, M.P. COVID-19–Induced New-Onset Diabetes: Trends and Technologies. Diabetes 2021, 70, 2733–2744.
  23. Montefusco, L.; Ben Nasr, M.; D’Addio, F.; Loretelli, C.; Rossi, A.; Pastore, I.; Daniele, G.; Abdelsalam, A.; Maestroni, A.; Dell’Acqua, M.; et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 2021, 3, 774–785.
  24. Ghosh, A.; Anjana, R.M.; Shanthi Rani, C.S.; Jeba Rani, S.; Gupta, R.; Jha, A.; Gupta, V.; Kuchay, M.S.; Luthra, A.; Durrani, S.; et al. Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab. Syndr. 2021, 15, 215–220.
  25. Sathish, T.; Kapoor, N.; Cao, Y.; Tapp, R.J.; Zimmet, P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes. Metab. 2021, 23, 870–874.
  26. Sathish, T.; Chandrika Anton, M. Newly diagnosed diabetes in patients with mild to moderate COVID-19. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 569–571.
  27. Unsworth, R.; Wallace, S.; Oliver, N.S.; Yeung, S.; Kshirsagar, A.; Naidu, H.; Kwong, R.M.W.; Kumar, P.; Logan, K.M. New-onset type 1 diabetes in children during COVID-19: Multicenter regional findings in the U.K. Diabetes Care 2020, 43, e170–e171.
  28. Tittel, S.R.; Rosenbauer, J.; Kamrath, C.; Ziegler, J.; Reschke, F.; Hammersen, J.; Mönkemöller, K.; Pappa, A.; Kapellen, T.; Holl, R.W. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care 2020, 43, e172–e173.
  29. Salmi, H.; Heinonen, S.; Hästbacka, J.; Lääperi, M.; Rautiainen, P.; Miettinen, P.J.; Vapalahti, O.; Hepojoki, J.; Knip, M. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch. Dis. Child. 2022, 107, 180–185.
  30. Kamrath, C.; Mönkemöller, K.; Biester, T.; Rohrer, T.R.; Warncke, K.; Hammersen, J.; Holl, R.W. Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020, 324, 801–804.
  31. Shrestha, D.B.; Budhathoki, P.; Raut, S.; Adhikari, S.; Ghimire, P.; Thapaliya, S.; Rabaan, A.A.; Karki, B.J. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J. Virol. 2021, 10, 275–287.
  32. Wu, R.; Mumtaz, M.; Maxwell, A.J.; Isaacs, S.R.; Laiho, J.E.; Rawlinson, W.D.; Hyöty, H.; Craig, M.E.; Kim, K.W. Respiratory infections and Type 1 diabetes: Potential roles in pathogenesis. Rev. Med. Virol. 2023, 33, e2429.
  33. Omotosho, Y.B.; Ying, G.W.; Stolar, M.; Mallari, A.J.P. COVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune Diabetes. Cureus 2021, 13, e12690.
  34. Marchand, L.; Pecquet, M.; Luyton, C. Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2020, 57, 1265–1266.
  35. Ssentongo, P.; Zhang, Y.; Witmer, L.; Chinchilli, V.M.; Ba, D.M. Association of COVID-19 with diabetes: A systematic review and meta-analysis. Sci. Rep. 2022, 12, 20191.
  36. Li, J.; Wang, X.; Chen, J.; Zuo, X.; Zhang, H.; Deng, A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes. Metab. 2020, 22, 1935–1941.
  37. Gentile, S.; Strollo, F.; Mambro, A.; Ceriello, A. COVID-19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them? Diabetes Obes. Metab. 2020, 22, 2507–2508.
  38. Rivero-Martín, M.J.; Rivas-Mercado, C.M.; Ceñal-González-Fierro, M.J.; López-Barrena, N.; Lara-Orejas, E.; Alonso-Martín, D.; Alfaro-Iznaola, C.; Alcázar-Villar, M.J.; Sánchez-Escudero, V.; González-Vergaz, A. Severity of new-onset type 1 diabetes in children and adolescents during the coronavirus-19 disease pandemic. Endocrinol. Diabetes y Nutr. 2022, 69, 810–815.
  39. Sathish, T.; Tapp, R.J.; Cooper, M.E.; Zimmet, P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021, 47, 101204.
  40. Alomar, F.A. Methylglyoxal in COVID-19-induced hyperglycemia and new-onset diabetes. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 8152–8171.
  41. Nunez Lopez, Y.O.; Iliuk, A.; Casu, A.; Parikh, A.; Smith, J.S.; Corbin, K.; Lupu, D.; Pratley, R.E. Extracellular vesicle proteomics and phosphoproteomics identify pathways for increased risk in patients hospitalized with COVID-19 and type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2023, 197, 110565.
  42. Stidsen, J.V.; Green, A.; Rosengaard, L.; Højlund, K. Risk of severe COVID-19 infection in persons with diabetes during the first and second waves in Denmark: A nationwide cohort study. Front. Endocrinol. 2022, 13, 1025699.
  43. Al-Sayyar, A.; Hulme, K.D.; Thibaut, R.; Bayry, J.; Sheedy, F.J.; Short, K.R.; Alzaid, F. Respiratory Tract Infections in Diabetes—Lessons From Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity. Front. Endocrinol. 2022, 13, 919223.
  44. Landstra, C.P.; de Koning, E.J.P. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front. Endocrinol. 2021, 12, 649525.
  45. Loza, A.; Wong-Chew, R.M.; Jiménez-Corona, M.E.; Zárate, S.; López, S.; Ciria, R.; Palomares, D.; García-López, R.; Iša, P.; Taboada, B.; et al. Two-year follow-up of the COVID-19 pandemic in Mexico. Front. Public Health 2023, 10, 1050673.
  46. Uchihara, M.; Sugiyama, T.; Bouchi, R.; Matsunaga, N.; Asai, Y.; Gatanaga, H.; Ohsugi, M.; Ohmagari, N.; Kajio, H.; Ueki, K. Association of acute-to-chronic glycemic ratio and outcomes in patients with COVID-19 and undiagnosed diabetes mellitus: A retrospective nationwide cohort study. J. Diabetes Investig. 2023, 14, 623–629.
  47. Uchihara, M.; Bouchi, R.; Kodani, N.; Saito, S.; Miyazato, Y.; Umamoto, K.; Sugimoto, H.; Kobayashi, M.; Hikida, S.; Akiyama, Y.; et al. Impact of newly diagnosed diabetes on coronavirus disease 2019 severity and hyperglycemia. J. Diabetes Investig. 2022, 13, 1086–1093.
  48. Vargas-Vázquez, A.; Bello-Chavolla, O.Y.; Ortiz-Brizuela, E.; Campos-Muñoz, A.; Mehta, R.; Villanueva-Reza, M.; Bahena-López, J.P.; Antonio-Villa, N.E.; González-Lara, M.F.; Ponce De León, A.; et al. Impact of undiagnosed Type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Res. Care 2021, 9, e002026.
  49. Miller, L.E.; Bhattacharyya, R.; Miller, A.L. Diabetes mellitus increases the risk of hospital mortality in patients with COVID-19: Systematic review with meta-analysis. Medicine 2020, 99, e22439.
  50. Sindi, A.A.; Tashkandi, W.A.; Jastaniah, M.W.; Bashanfar, M.A.; Fakhri, A.F.; Alsallum, F.S.; Alguydi, H.B.; Elhazmi, A.; Al-Khatib, T.A.; Alawi, M.M.; et al. Impact of diabetes mellitus and co-morbidities on mortality in patients with COVID-19: A single-center retrospective study. Saudi Med. J. 2023, 44, 67–73.
  51. Zhang, T.; Mei, Q.; Zhang, Z.; Walline, J.H.; Liu, Y.; Zhu, H.; Zhang, S. Risk for newly diagnosed diabetes after COVID-19: A systematic review and meta-analysis. BMC Med. 2022, 20, 444.
  52. Reynolds, R.M.; Labad, J.; Sears, A.V.; Williamson, R.M.; Strachan, M.W.J.; Deary, I.J.; Lowe, G.D.O.; Price, J.F.; Walker, B.R. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: The Edinburgh Type 2 Diabetes Study. Eur. J. Endocrinol. 2012, 166, 861–868.
  53. Kim, Y.; Park, S.; Oh, K.; Choi, H.; Jeong, E.K. Changes in the management of hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: Data from the 2010–2020 Korea National Health and Nutrition Examination Survey. Epidemiol. Health 2023, 45, e2023014.
  54. Carr, M.J.; Wright, A.K.; Leelarathna, L.; Thabit, H.; Milne, N.; Kanumilli, N.; Ashcroft, D.M.; Rutter, M.K. Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK. Lancet Diabetes Endocrinol. 2021, 9, 413–415.
  55. Carr, M.J.; Wright, A.K.; Leelarathna, L.; Thabit, H.; Milne, N.; Kanumilli, N.; Ashcroft, D.M.; Rutter, M.K. Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: A UK-wide cohort study involving 618 161 people in primary care. BMJ Qual. Saf. 2022, 31, 503–514.
  56. Capra, M.E.; Stanyevic, B.; Giudice, A.; Monopoli, D.; Decarolis, N.M.; Esposito, S.; Biasucci, G. The Effects of COVID-19 Pandemic and Lockdown on Pediatric Nutritional and Metabolic Diseases: A Narrative Review. Nutrients 2022, 15, 88.
  57. Quinn, L.M.; Wong, F.S.; Narendran, P. Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality. Front. Immunol. 2021, 12, 737964.
  58. Chee, Y.J.; Ng, S.J.H.; Yeoh, E. Diabetic ketoacidosis precipitated by COVID-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res. Clin. Pract. 2020, 164, 108166.
  59. Taplin, C.; Barker, J. Autoantibodies in type 1 diabetes. Autoimmunity 2008, 41, 11–18.
  60. Steenblock, C.; Hassanein, M.; Khan, E.G.; Yaman, M.; Kamel, M.; Barbir, M.; Lorke, D.E.; Rock, J.A.; Everett, D.; Bejtullah, S.; et al. Diabetes and COVID-19: Short- and Long-Term Consequences. Horm. Metab. Res. 2022, 54, 503–509.
  61. Mamtani, M.; Athavale, A.; Abraham, M.; Vernik, J.; Amarah, A.; Ruiz, J.; Joshi, A.; Itteera, M.; Zhukovski, S.; Madaiah, R.; et al. Association of hyperglycaemia with hospital mortality in nondiabetic COVID-19 patients: A cohort study. Diabetes Metab. 2021, 47, 101254.
  62. Chourasia, P.; Goyal, L.; Kansal, D.; Roy, S.; Singh, R.; Mahata, I.; Sheikh, A.B.; Shekhar, R. Risk of New-Onset Diabetes Mellitus as a Post-COVID-19 Condition and Possible Mechanisms: A Scoping Review. J. Clin. Med. 2023, 12, 1159.
  63. Bally, K.; Ji, B.; Soni, L. COVID-19 Vaccine-Induced Latent Autoimmune Diabetes in Adults. Cureus 2023, 15, e33762.
  64. Lin, R.; Lin, Y.W.; Chen, M.H. Fulminant Type 1 Diabetes Mellitus after SARS-CoV-2 Vaccination: A Case Report. Vaccines 2022, 10, 1905.
  65. Kshetree, B.; Lee, J.; Acharya, S. COVID-19 Vaccine-Induced Rapid Progression of Prediabetes to Ketosis-Prone Diabetes Mellitus in an Elderly Male. Cureus 2022, 14, e28830.
  66. Moon, H.; Suh, S.; Park, M.K. Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination. J. Korean Med. Sci. 2023, 38, e12.
  67. Abu-Rumaileh, M.A.; Gharaibeh, A.M.; Gharaibeh, N.E. COVID-19 Vaccine and Hyperosmolar Hyperglycemic State. Cureus 2021, 13, e14125.
  68. Edwards, A.E.; Vathenen, R.; Henson, S.M.; Finer, S.; Gunganah, K. Acute hyperglycaemic crisis after vaccination against COVID-19: A case series. Diabet. Med. J. Br. Diabet. Assoc. 2021, 38, e14631.
  69. Mishra, A.; Ghosh, A.; Dutta, K.; Tyagi, K.; Misra, A. Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: Report of three cases. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 102151.
  70. Wan, E.Y.F.; Chui, C.S.L.; Mok, A.H.Y.; Xu, W.; Yan, V.K.C.; Lai, F.T.T.; Li, X.; Wong, C.K.H.; Chan, E.W.Y.; Lui, D.T.W.; et al. mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study. Drug Saf. 2022, 45, 1477–1490.
  71. Gouda, N.; Dimitriadou, M.; Sotiriou, G.; Christoforidis, A. The impact of COVID-19 vaccination on glycaemic control in children and adolescents with type 1 diabetes mellitus on continuous glucose monitoring. Acta Diabetol. 2022, 59, 1609–1614.
  72. López-Contreras, J.E.; Paredes-Casillas, P.; Morales-Romero, J.; Castillo-Vélez, F.E.; Lona-Reyes, J.C.; Bedolla-Barajas, M. Incidence and factors associated with early and late adverse reactions after the first dose of Pfizer-BioNTech vaccine among healthcare workers. Cir. Cir. 2023, 91, 34–41.
  73. Mallhi, T.H.; Khan, Y.H.; Butt, M.H.; Salman, M.; Tanveer, N.; Alotaibi, N.H.; Alzarea, A.I.; Alanazi, A.S. Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia. Medicina 2022, 58, 1799.
  74. Xiang, F.; Long, B.; He, J.; Cheng, F.; Zhang, S.; Liu, Q.; Chen, Z.; Li, H.; Chen, M.; Peng, M.; et al. Impaired antibody responses were observed in patients with Type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines. Virol. J. 2023, 20, 22.
  75. Paar, M.; Aziz, F.; Sourij, C.; Tripolt, N.J.; Kojzar, H.; Müller, A.; Pferschy, P.; Obermayer, A.; Banfic, T.; Di Geronimo Quintero, B.; et al. Only Subclinical Alterations in the Haemostatic System of People with Diabetes after COVID-19 Vaccination. Viruses 2022, 15, 10.
  76. Heald, A.H.; Jenkins, D.A.; Williams, R.; Mudaliar, R.N.; Naseem, A.; Davies, K.A.B.; Gibson, J.M.; Peng, Y.; Ollier, W. COVID-19 Vaccination and Diabetes Mellitus: How Much Has It Made a Difference to Outcomes Following Confirmed COVID-19 Infection? Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord. 2023, 14, 193–204.
  77. Kwan, A.C.; Ebinger, J.E.; Botting, P.; Navarrette, J.; Claggett, B.; Cheng, S. Association of COVID-19 Vaccination With Risk for Incident Diabetes After COVID-19 Infection. JAMA Netw. Open 2023, 6, e2255965.
  78. Cheng, Y.; Shen, P.; Tao, Y.; Zhang, W.; Xu, B.; Bi, Y.; Han, Z.; Zhou, Y.H. Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 in diabetic individuals. Front. Public Health 2022, 10, 1025901.
  79. Virgilio, E.; Trevisan, C.; Abbatecola, A.; Malara, A.; Palmieri, A.; Fedele, G.; Stefanelli, P.; Leone, P.; Schiavoni, I.; Maggi, S.; et al. Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study. Diabetes Care 2022, 45, 2935–2942.
  80. van den Berg, J.M.; Remmelzwaal, S.; Blom, M.T.; van Hoek, B.A.C.E.; Swart, K.M.A.; Overbeek, J.A.; Burchell, G.L.; Herings, R.M.C.; Elders, P.J.M. Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review. Vaccines 2022, 11, 24.
  81. D’Onofrio, L.; Fogolari, M.; Amendolara, R.; Siena, A.; De Fata, R.; Davini, F.; Coraggio, L.; Mignogna, C.; Moretti, C.; Maddaloni, E.; et al. Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a 6 months follow-up study: The CoVaDiab study I. Diabetes/Metabolism Res. Rev. 2023, 39, e3601.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback